Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) · Sponsor: ADARx Pharmaceuticals, Inc.
The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).
This description comes directly from the study's public registry record.
Stephanie Leyva · 877-232-7974 · info@adarx.com
Always discuss trial participation with your own doctor first.
| Nucleus Network Brisbane | Brisbane, Queensland, Australia | Completed |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Completed |
| Royal Melbourne Hospital | Parkville, Victoria, Australia | Recruiting |
| Richmond Pharmacology Ltd | London, London, United Kingdom | Completed |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05876312